Skip to main content
. 2022 Sep 8;82(21):4058–4078. doi: 10.1158/0008-5472.CAN-22-1731

Figure 4.

Figure 4. Differential comutation patterns in KRAS- and NRAS-mutant tumors point to RAS/non-RAS gene dependencies based on host features and cancer lineage. Differential RAS-mutant allele comutation patterns per tumor type and by age, race, and sex for KRAS/ATM in NSCLC (A), KRAS/RBM10 in NSCLC (B), KRAS/NTRK3 in NSCLC (C), KRAS/STK11 in NSCLC (D), KRAS/KEAP1 in NSCLC (E), KRAS/EGFR in NSCLC (F), KRAS/PIK3CA in colorectal carcinoma (G), KRAS/FBXW7 in colorectal carcinoma (H), KRAS/RNF43 in colorectal carcinoma (I), KRAS/SF3B1 in colorectal carcinoma (J), KRAS/BRAF in colorectal carcinoma (K), KRAS/TP53 in colorectal carcinoma (L), KRAS/TP53 in PAC (M), KRAS/SMAD4 in PAC (N), KRAS/CDKN2A in PAC (O), KRAS/DAX in PAC (P), KRAS/MEN1 in PAC (Q), KRAS/CASP8 in colorectal carcinoma (R), NRAS/BRAF in melanoma (S), NRAS/TERT in melanoma (T), KRAS/NF1 in melanoma (U), KRAS/PTEN in uterine cancer (V), KRAS/TP53 in uterine cancer (W) and NRAS/BRAF in thyroid cancer (X). Log OR is plotted for each stratified RAS/non-RAS comutation, red indicates co-occurrence and blue indicates mutual exclusivity or occurrence less frequently than expected under independence. CRC, colorectal cancer; NSCLC, non–small cell lung cancer; PAC, pancreatic adenocarcinoma.

Differential comutation patterns in KRAS- and NRAS-mutant tumors point to RAS/non-RAS gene dependencies based on host features and cancer lineage. Differential RAS-mutant allele comutation patterns per tumor type and by age, race, and sex for KRAS/ATM in NSCLC (A), KRAS/RBM10 in NSCLC (B), KRAS/NTRK3 in NSCLC (C), KRAS/STK11 in NSCLC (D), KRAS/KEAP1 in NSCLC (E), KRAS/EGFR in NSCLC (F), KRAS/PIK3CA in colorectal carcinoma (G), KRAS/FBXW7 in colorectal carcinoma (H), KRAS/RNF43 in colorectal carcinoma (I), KRAS/SF3B1 in colorectal carcinoma (J), KRAS/BRAF in colorectal carcinoma (K), KRAS/TP53 in colorectal carcinoma (L), KRAS/TP53 in PAC (M), KRAS/SMAD4 in PAC (N), KRAS/CDKN2A in PAC (O), KRAS/DAX in PAC (P), KRAS/MEN1 in PAC (Q), KRAS/CASP8 in colorectal carcinoma (R), NRAS/BRAF in melanoma (S), NRAS/TERT in melanoma (T), KRAS/NF1 in melanoma (U), KRAS/PTEN in uterine cancer (V), KRAS/TP53 in uterine cancer (W), and NRAS/BRAF in thyroid cancer (X). Log OR is plotted for each stratified RAS/non-RAS comutation. Red, co-occurrence; blue, mutual exclusivity or occurrence less frequently than expected under independence. CRC, colorectal cancer.